Good News for Galapagos

September 17, 2018 News BioVox

It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short amount of time, launched their initial public offering (IPO) on the American stock./. market, raised $300 Mil within the first few hours of going public as well as seen several positive developments in clinical trials. Not to mention, the collaboration agreement regarding drug candidate MOR106, with Novartis and partner MorphoSys, coming into effect.

It’s safe to say, this Belgian behemoth is on a roll and things don’t look to be slowing down anytime soon. Experts predicted 2018 to be a good year for Belgian Biotech and life sciences companies; business is certainly living up to expectations so far. At BioVox, we are excited to see what the remaining months of the year will bring!

Galapagos news

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
06 September 2018 – Read the press release here.

Gilead Sciences and Galapagos announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis.

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS
11 September 2018 – Read the press release here.

Gilead Sciences and Galapagos announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to biologic agents, achieved its primary endpoint.

• Filgotinib 100 mg and 200 mg Doses Achieved Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response to Biologic Agents.
• Both Filgotinib Doses also Achieved All Key Secondary Efficacy Endpoints, including Low Disease Activity and Clinical Remission.
• Tolerability of Filgotinib was Consistent with Previously Reported Studies.

MORPHOSYS AND GALAPAGOS ANNOUNCE US ANTITRUST CLEARANCE FOR GLOBAL LICENSE AGREEMENT FOR MOR106 WITH PHARMA PARTNER
12 September 2018 – Read the press release here.

Galapagos and MorphoSys announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106.

GALAPAGOS ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING
12 September 2018 – Read the press release here.

Galapagos announced that it intended to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares in a U.S. public offering.

GALAPAGOS RAISES $300 MILLION GROSS PROCEEDS IN A US PUBLIC OFFERING
13 September 2018 – Read the press release here.

Galapagos announced the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares at $116.50 per ADS, before underwriting discounts.

GALAPAGOS AND MORPHOSYS ANNOUNCE START OF A PHASE I SUBCUTANEOUS BRIDGING STUDY WITH MOR106
13 September 2018 – Read the press release here.

Galapagos and MorphoSys announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.

GALAPAGOS ANNOUNCES CLOSING OF PUBLIC OFFERING OF AMERICAN DEPOSITORY SHARES FOR GROSS PROCEEDS OF €296.2 MILLION
17 September 2018 – Read the press release here.

Galapagos  announced the closing of its underwritten public offering of 2,961,373 American Depositary Shares at a price of $116.50, before underwriting discounts, for gross proceeds of €296.2 million.

GALAPAGOS ISSUES NEW SHARES AS RESULT OF PUBLIC OFFERING
17 September 2018 – Read the press release here.

Galapagos announces a share capital increase as a result of a public offering of American Depositary Shares.


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts